The impact of pharmaceutical innovation on disability days and the use of medical services in the United States, 1997–2010

Journal of Human Capital

Volumn 8, Issue 4, 2014, Pages 432-480

  Lichtenberg, Frank R ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929304035     PISSN: 19328575     EISSN: 19328664     Source Type: Journal    
DOI: 10.1086/679110     Document Type: Article

References (30)

1. Acemoglu, D., and J. Linn. 2004. “Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry.” Q.J.E. 119 (August): 1049–90.
2. Australian Productivity Commission. 2005. Impacts of Advances inMedical Technology in Australia. Research Report. Melbourne: Australian Productivity Comm. http://www.pc.gov.au/_data/assets/pdf_file/0003/17193/medicaltechnology.pdf.
3. Baltagi, B. H., F. Moscone, and E. Tosetti. 2012. “Medical Technology and the Production of Health Care.” Empirical Econ. 42 (2): 395–411.
4. Becker, G. S. 1964. Human Capital. New York: Columbia Univ. Press (for NBER).
5. Center for Medicare and Medicaid Services. 2013. National Health Expenditure Data. http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/tables.pdf.
6. Dorsey, E. R., et al. 2010. “Financial Anatomy of Biomedical Research, 2003–2008.” J. American Medical Assoc. 303 (2): 137–43.
7. Duflos, G., and F. R. Lichtenberg. 2012. “Does Competition Stimulate Drug Utilization? The Impact of Changes in Market Structure on US Drug Prices, Marketing and Utilization.” Internat. Rev. Law and Econ. 32 (March): 95–109.
8. Ehrlich, I., and Y. Yin. 2013. “Equilibrium Health Spending and Population Aging in a Model of Endogenous Growth: Will the GDP Share of Health Spending Keep Rising?” J. Human Capital 7 (4): 411–47.
9. Food and Drug Administration. 2013a. Approval Times for New Molecular Entity Drugs (NMEs) and New Biologics (New BLAs), 1993–2008. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDeveloped andApproved/DrugandBiologicApprovalReports/UCM123959.pdf.
10. Food and Drug Administration. 2013b. Drug Approvals and Databases > Drugs@FDA Frequently Asked Questions. http://www.fda.gov/Drugs/InformationOnDrugs/ucm075234.htm#chemtype_reviewclass.
11. Food and Drug Administration. 2013c. How Drugs Are Developed and Approved. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/default.htm.
12. Fuchs, V. R. 1966. “The Contribution of Health Services to the American Economy.” Milbank Memorial Fund Q. 44:65–102.
13. Grossman, G. M., and E. Helpman. 1991. “Quality Ladders in the Theory of Growth.” Rev. Econ. Studies 58 (1): 43–61.
14. Grossman, M. 2000. “The Human Capital Model.” In Handbook of Health Economics, vol. 1, edited by A. J. Culyer and J. P. Newhouse, 347–408. Amsterdam: Elsevier.
15. Hall, D. V., S. C. Jones, and J. Hoek. 2011. “Direct to Consumer Advertising versus Disease Awareness Advertising: Consumer Perspectives from Down Under.” J. Public Affairs 11:60–69.
16. Harper, M. J. 2007. “Technology and the Theory of Vintage Aggregation.” In Hardto- Measure Goods and Services: Essays inHonor of Zvi Griliches, editedby E.R.Berndt and C. R. Hulten, 99–120. Chicago: Univ. Chicago Press (for NBER). http://www.nber.org/chapters/c0875.
17. Jalan, J., and M. Ravallion. 2001. “Does PipedWater Reduce Diarrhea for Children in Rural India?” Policy ResearchWorking Paper no. 2664, World Bank Development Research Group, Washington, DC. http://www1.worldbank.org/prem/poverty/ie/dime_papers/332.pdf.
18. Kavanaugh, A., et al. 2006. “Effect of Infliximab Therapy on Employment, Time Lost from Work, and Productivity in Patients with Psoriatic Arthritis.” J. Rheumatology 33 (November): 2254–59.
19. Lichtenberg, F. R. 2005. “Availability of New Drugs and Americans’ Ability to Work.” J. Occupational and Environmental Medicine 47:373–80.
20. Lichtenberg, F. R. 2011a. “Has Pharmaceutical Innovation Reduced Social Security Disability Growth?” Internat. J. Econ. Bus. 18 (July): 293–316.
21. Lichtenberg, F. R. 2011b. “The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth.” Internat. J. Health Care Finance and Econ. 11 (1): 1–34.
22. Lichtenberg, F. R.. 2014. “The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in France, 2000–2009.” Econ. and Human Biology 13:107–27.
23. Lichtenberg, F. R., and B. Pettersson. 2014. “The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997–2010: Evidence from Longitudinal, Disease-Level Data.” Econ. Innovation and New Technology 23 (3): 239–73.
24. Mushkin, S. J. 1962. “Health as an Investment.” J.P.E. 70, no. 5, pt. 2 (October): 129–57.
25. National Science Foundation. 2014. U.S. Corporate R&D, vol. 1, Top 500 Firms in R&D by Industry Category. http://www.nsf.gov/statistics/nsf00301/expendit.htm#intensity.
26. Sampat, B. N., and F. R. Lichtenberg. 2011. “What Are the Respective Roles of the Public and Private Sectors in Pharmaceutical Innovation?” Health Affairs 30 (2): 332–39.
27. Solow, Robert M. 1960. “Investment and Technological Progress.” In Mathematical Methods in Social Sciences 1959, edited by K. Arrow, S. Karlin, and P. Suppes, 89–104. Stanford, CA: Stanford Univ. Press.
28. Stukel, T. A., E. S. Fisher, D. E. Wennberg, D. A. Alter, D. J. Gottlieb, and M. J. Vermeulen. 2007. “Analysis of Observational Studies in the Presence of Treatment Selection Bias: Effects of Invasive Cardiac Management on AMI Survival Using Propensity Score and Instrumental Variable Methods.” J. American Medical Assoc. 297 (3): 278–85. http://jama.jamanetwork.com/article.aspx?articleid5205172.
29. US. Bureau of the Census. 1972. Statistical Abstract of the United States. Washington, DC: US Bur. Census.
30. van Vollenhoven, R. F., M. A. Cifaldi, S. Ray, N. Chen, and M. H. Weisman. 2010. “Improvement inWork Place andHousehold Productivity for Patients with Early Rheumatoid Arthritis Treated with Adalimumab Plus Methotrexate: Work Outcomes and Their Correlations with Clinical and Radiographic Measures from a Randomized Controlled Trial Companion Study.” Arthritis Care Res. 62 (February): 226–34.